A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease. Signal12 ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...